导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.42% | 1884/4773 |
| 近一周 | -1.55% | 510/5462 |
| 近一月 | -1.32% | 912/5421 |
| 近一季 | -3.82% | 1477/5209 |
| 近半年 | -9.29% | 3476/4920 |
| 近一年 | 4.61% | 1692/4366 |
| 近两年 | 29.25% | 2304/2954 |
| 近三年 | 19.39% | 1490/2253 |
| 成立以来 | 76.86% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.22% 782/4961 |
1.75% 2994/5312 |
- - |
- - |
| 2025 | 6.18% 2970/4813 |
-4.44% 3177/3635 |
0.90% 2536/4076 |
6.79% 3510/4524 |
3.12% 742/4813 |
| 2024 | 18.19% 620/3463 |
9.11% 146/2808 |
1.80% 444/3014 |
6.90% 2829/3129 |
-0.46% 1429/3463 |
| 2023 | 5.94% 178/2656 |
14.81% 231/2280 |
1.12% 237/2385 |
-3.34% 900/2515 |
-5.60% 1408/2655 |
| 2022 | -11.84% 261/2207 |
-10.36% 396/1919 |
2.50% 1293/2016 |
-9.23% 260/2113 |
5.70% 446/2208 |
| 2021 | 24.10% 125/1822 |
2.19% 226/1255 |
3.24% 978/1330 |
16.37% 74/1466 |
1.09% 1008/1822 |
| 2020 | 7.77% 862/1250 |
-9.28% 667/1028 |
-0.38% 1017/1067 |
8.92% 692/1164 |
9.48% 638/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实央企创新驱动ETF联接C VS. 长安沪深300非周期A(740101) |